{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T16:59:53Z","timestamp":1761238793329,"version":"3.37.3"},"reference-count":12,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2020,11,9]],"date-time":"2020-11-09T00:00:00Z","timestamp":1604880000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Systemic inflammatory and autoimmune diseases can be associated with myelodysplastic syndromes. Current treatments (steroids, immunosuppressive agents, biologics) are unsatisfactory because of their low response rate, dependence or adverse events. We aimed at evaluating the effects of low doses of IL-2 (ld-IL2) as a regulatory T-cell inducer in this context.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We treated three patients with ld-IL2 with myelodysplastic syndromes and an associated dysimmune disorder (polymyalgia rheumatic, relapsing polychondritis associated with Sweet\u2019s syndrome and vasculitis with cutaneous and joint involvement, respectively). All three patients were dependent on steroids and refractory to biologics or azacitidine. They received doses of 1\u20131.5 million units of proleukin\/day during 5\u2009days and then every fortnight.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The treatment led to a clinical improvement and steroid sparing in 2\/3 patients with no serious adverse events, and no progression of the disease.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Our results support the investigation of ld-IL2 in MDS associated with immune disorders in controlled clinical studies.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keaa696","type":"journal-article","created":{"date-parts":[[2020,10,8]],"date-time":"2020-10-08T19:19:28Z","timestamp":1602184768000},"page":"3404-3408","source":"Crossref","is-referenced-by-count":5,"title":["Low dose IL-2 in patients with steroid-dependent dysimmune manifestations associated with myelodysplastic syndromes: a three-case report"],"prefix":"10.1093","volume":"60","author":[{"given":"Marion","family":"Corfmat","sequence":"first","affiliation":[{"name":"Service de M\u00e9decine Interne, IUCT Oncop\u00f4le, Centre Hospitalier Universitaire de Toulouse, Toulouse"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christophe","family":"Willekens","sequence":"additional","affiliation":[{"name":"D\u00e9partement d\u2019H\u00e9matologie, Institut Gustave Roussy, Universit\u00e9 Paris Sud, Villejuif"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julien","family":"Vinit","sequence":"additional","affiliation":[{"name":"Service de M\u00e9decine Interne, CHWM, 4, Rue Capitaine-Drillien, Chalon-sur-Sa\u00f4ne"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillaume","family":"Bussone","sequence":"additional","affiliation":[{"name":"Service de M\u00e9decine Interne, Immunologie Clinique, M\u00e9decine Aig\u00fce Polyvalente, H\u00f4pital Antoine-B\u00e9cl\u00e8re\u2014AP-HP, Clamart"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Fenaux","sequence":"additional","affiliation":[{"name":"Service d'H\u00e9matologie S\u00e9niors H\u00f4pital Saint-Louis, Assistance Publique - H\u00f4pitaux de Paris, Universit\u00e9 de Paris"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Fain","sequence":"additional","affiliation":[{"name":"Service de M\u00e9decine Interne, AP-HP, H\u00f4pital Saint Antoine, Sorbonne Universit\u00e9"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Klatzmann","sequence":"additional","affiliation":[{"name":"INSERM, Immunology-Immunopathology-Immunotherapy (i3), Sorbonne Universit\u00e9"},{"name":"Clinical Investigation Center for Biotherapies (CIC-BTi) and Immunology-Inflammation-Infectiology and Dermatology Department (3iD), AP-HP, H\u00f4pital Piti\u00e9-Salp\u00eatri\u00e8re, Paris"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2849-3049","authenticated-orcid":false,"given":"Arsene","family":"Mekinian","sequence":"additional","affiliation":[{"name":"Service de M\u00e9decine Interne, AP-HP, H\u00f4pital Saint Antoine, Sorbonne Universit\u00e9"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6891-9238","authenticated-orcid":false,"given":"Thibault","family":"Comont","sequence":"additional","affiliation":[{"name":"Service de M\u00e9decine Interne, IUCT Oncop\u00f4le, Centre Hospitalier Universitaire de Toulouse, Toulouse"},{"name":"Centre de Recherche en Canc\u00e9rologie de Toulouse, Inserm UMR 1037, Toulouse, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"MINHEMON (French network of dysimmune disorders associated to hematological malignancies)","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,11,9]]},"reference":[{"key":"2021070122135881400_keaa696-B1","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.autrev.2018.07.009","article-title":"Autoimmune diseases in myelodysplastic syndrome favors patients survival: a case control study and literature review","volume":"18","author":"Seguier","year":"2019","journal-title":"Autoimmun Rev"},{"key":"2021070122135881400_keaa696-B2","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1007\/s00277-018-3472-9","article-title":"Autoimmune manifestations associated with myelodysplastic syndromes","volume":"97","author":"Grignano","year":"2018","journal-title":"Ann Hematol"},{"key":"2021070122135881400_keaa696-B3","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.autrev.2017.07.003","article-title":"Biologics in myelodysplastic syndrome-related systemic inflammatory and autoimmune diseases: french multicenter retrospective study of 29 patients","volume":"16","author":"Mekinian","year":"2017","journal-title":"Autoimmun Rev"},{"key":"2021070122135881400_keaa696-B4","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.leukres.2016.02.005","article-title":"Efficacy of Azacitidine in autoimmune and inflammatory disorders associated with myelodysplastic syndromes and chronic myelomonocytic leukemia","volume":"43","author":"Fraison","year":"2016","journal-title":"Leuk Res"},{"key":"2021070122135881400_keaa696-B5","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.critrevonc.2017.12.013","article-title":"Immune dysregulation in myelodysplastic syndrome: clinical features, pathogenesis and therapeutic strategies","volume":"122","author":"Wang","year":"2018","journal-title":"Crit Rev Oncol Hematol"},{"key":"2021070122135881400_keaa696-B6","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1002\/cncr.23851","article-title":"Cancer-specific survival outcomes among patients treated during the cytokine era of kidney cancer (1989-2005): a benchmark for emerging targeted cancer therapies","volume":"113","author":"Belldegrun","year":"2008","journal-title":"Cancer"},{"key":"2021070122135881400_keaa696-B7","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/nri3823","article-title":"The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases","volume":"15","author":"Klatzmann","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"2021070122135881400_keaa696-B8","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1056\/NEJMoa1105143","article-title":"Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis","volume":"365","author":"Saadoun","year":"2011","journal-title":"N Engl J Med"},{"key":"2021070122135881400_keaa696-B9","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1136\/annrheumdis-2019-215396","article-title":"Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial","volume":"79","author":"He","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2021070122135881400_keaa696-B10","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1136\/annrheumdis-2018-214229","article-title":"Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial","volume":"78","author":"Rosenzwajg","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2021070122135881400_keaa696-B11","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1093\/rheumatology\/kev294","article-title":"Systemic inflammatory and autoimmune manifestations associated with myelodysplastic syndromes and chronic myelomonocytic leukaemia: a French multicentre retrospective study","volume":"55","author":"Mekinian","year":"2016","journal-title":"Rheumatology"},{"key":"2021070122135881400_keaa696-B12","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1046\/j.1365-2141.1998.00672.x","article-title":"A phase II trial of interleukin-2 in myelodysplastic syndromes","volume":"101","author":"Nand","year":"1998","journal-title":"Br J Haematol"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/60\/7\/3404\/38849909\/keaa696.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/60\/7\/3404\/38849909\/keaa696.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T22:19:55Z","timestamp":1625177995000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/60\/7\/3404\/5961489"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,9]]},"references-count":12,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2020,11,9]]},"published-print":{"date-parts":[[2021,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaa696","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"type":"print","value":"1462-0324"},{"type":"electronic","value":"1462-0332"}],"subject":[],"published-other":{"date-parts":[[2021,7,1]]},"published":{"date-parts":[[2020,11,9]]}}}